Risk factors
Starling Oncology (STLN) risk factors
Item 1A of every Starling Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors50 risks4 new7 dropped12 reworded
Federal net operating losses increased to $227,510,540 as of December 31, 2025. Common warrants from the 2025 Private Placement reached 8,216,918 shares. Nasdaq listing compliance and pharmacy benefit manager reliance introduced new operational threats.
Filed Mar 12, 2026 - FY2024 10-K risk factors53 risks
Starling Oncology relies heavily on opening and acquiring new TOI PC clinics, with about 85% of 2024 revenue generated in California. The business faces significant financial risks from net losses, a capitation reimbursement model, and strict healthcare regulations.
Filed Mar 26, 2025